aranidipine

Aranidipine is a dihydropyridine-type calcium channel blocker used primarily for the treatment of hypertension and angina pectoris. It acts by inhibiting the influx of calcium ions through L-type calcium channels in vascular smooth muscle cells, leading to vasodilation and reduced blood pressure. Aranidipine also exhibits selective alpha2-adrenoreceptor antagonism, further contributing to its antihypertensive effects. The drug gives rise to two active metabolites (M-1α and M-1β) that retain hypotensive activity. Developed by Maruko Seiyaku and introduced by Taiho, aranidipine was launched in Japan in 1997 under the brand name Sapresta[2][5][7]. Its pharmacological profile includes long-lasting vasodilating actions on both afferent and efferent arterioles[6].

Brand names

Sapresta

Other names

aranidipine3DMOLSDF3D-SDFPDBSMILESInChI